Triple-negative breast cancer (TNBC), accounts for about 10–15% of all breast cancer cases, and this is due to the lack of immunohistological expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene PGR and triple-negative breast carcinoma.